Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 41.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

Tue, 25th May 2021 17:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Webis Holdings PLC - Isle of Man-based gaming firm - Receives West Virginia wagering license which allows company to accept online wagers from state residents. "We are delighted to receive this license from the West Virginia Racing Commission for WatchandWager. We believe that this license will be mutually beneficial to both the company and the state in the forms of revenue and taxes generated from wagering," says Webis.

----------

Revolution Bars Group PLC - bars operator based in Ashton-under-Lyne, England - Intends to raise GBP21.0 million via a firm placing, placing and an open offer at 20 pence per share. Says proceeds will go towards indebtedness, accelerate its existing site refurbishment programme and to take advantage of favourable market conditions for estate expansion.

----------

JPMorgan Global Core Real Assets Ltd - real estate, transportation and infrastructure investor - Says further USD13.8 million of committed capital called, with a funding date no later than June 7. "This capital is being called by the Asia-Pacific Real Estate Strategy and materially increases the exposure to industrial/ logistics assets within the property allocation," says JPMorgan Global Core. Says it has now invested 96% of the total capital raised from proceeds of both the IPO and all subsequent share issuance.

----------

Tiziana Life Sciences PLC - London-based therapeutics for oncology, inflammation and infectious diseases - Says the first patient with secondary progressive multiple sclerosis was dosed with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody. Says this is the first-ever clinical study in SPMS patients, under an individual patient expanded access IND, and will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. "Effective and targeted treatments for progressive MS are urgently needed. Nasal Foralumab could revolutionize treatment for this disabling form of disease," says Tanuja Chitnis, professor of neurology at Harvard Medical School.

----------

Mothercare PLC - Hemel Hempstead, England-based retailer to parents and young children - Reports unaudited net worldwide sales of GBP326 million for the year to March 27, down 40% to a year prior, impacted by varied approaches to Covid-19 in franchisee markets. "As a global brand the impact of Covid-19 has varied enormously by market as the countries in which our franchise partners operate have addressed the Covid-19 pandemic in many different ways including, but not limited to, restrictions on travel, movement and operating hours of retailers. These issues have been compounded by similar restrictions for our manufacturing partners, which coupled with the disruption to the global movement of freight, have caused additional challenges with availability of product for franchise partners further impacting sales for the year," says Mothercare. Expects to report a "small" earnings before interest, depreciation and amortisation profit for the year. Sees annual operating profit of GBP15 million "in future years" .

----------

Custodian REIT PLC - Leicester, England-based commercial real estate investor - Sells retail unit in Nottingham at auction for GBP700,000, in line with the most recent valuation. Says the disposal has reduced the Company's high street retail sector weighting by income from 10% to 9%. "This asset was not aligned with the strategy of the Company as we did not anticipate future rental recovery," says Custodian.

----------

Baillie Gifford UK Growth Fund PLC - investment firm focused on capital growth over the long-term from investment primarily in shares of listed UK companies - Announces name change to Baillie Gifford UK Growth Trust, effective Wednesday. The trading symbol and ISIN are to stay the same.

----------

Octopus Titan VCT PLC - venture capital trust - Announces that terms have been agreed for Snap Inc to acquire WaveOptics Ltd "at a value not materially different from its holding value". WaveOptics is a business that designs and sells a set of components for use in augmented reality glasses that allow for the creation of AR displays. Titan gas invested around GBP16.0 million in WaveOptics.

----------

IronRidge Resources Ltd - Australia-based minerals exploration company - Reports additional broad and high-grade lithium pegmatite drill intersections at new targets adjacent to the Ewoyaa lithium project in Ghana. "We are highly encouraged with the ongoing results received, which continue to confirm additional high grades in new exploration targets tested within the ELP area," says IronRidge.

----------

Sareum Holdings PLC - Cambridge-based drug development firm - Says Covid-19 continues to impact the contract research organisations with which Sareum is working to complete the preclinical development of SDC-1801 for autoimmune disease. "While initially the impact on development timelines was minimal, it has increased and is causing further delays to the conduct of the final preclinical studies the company needs to complete on SDC-1801 prior to filing an exploratory Clinical Trial Application," says Sareum. Says it now expects final toxicity and safety studies to complete in the third quarter of the year.

----------

Epwin Group PLC - Solihull, England-based building products manufacturer - Says demand from the group's key markets continues to be high, with indicators of consumer confidence strengthening. Revenue for the first four months of the year are 56% ahead of 2020, which included the first lockdown period, and 9% ahead of 2019. "The outlook for the current year continues to be favourable, notwithstanding the raw material cost inflation and supply chain issues, which we are managing proactively. The medium and long-term drivers for the Group's markets also remain positive, with a shortage of housing, an ageing and underinvested housing stock, as well as environmental and safety concerns driving legislation and initiatives that will require improvements to homes on a larger scale than just essential maintenance," says Epwin.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
13 Jun 2019 15:49

Sareum Plans To Start Human Trials Of Two Drug Candidates In 2020

(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in

Read more
3 Jun 2019 17:38

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint

Read more
3 Jun 2019 10:02

Sareum Reports Positive Data From Trials Of SRA737 In Advanced Cancer

LONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a

Read more
4 Mar 2019 10:58

Sareum Interim Loss Deepens On Costs As Pipeline Continues Progress

LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to

Read more
4 Mar 2019 08:26

Sareum's loss widens as development costs expand

(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.

Read more
28 Feb 2019 14:33

Sareum flags potentially significant findings for SRA737

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.

Read more
11 Dec 2018 15:55

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to

Read more
30 Nov 2018 11:48

Sareum Reports Efficacy Data For Immunotherapy Combination With SRA737

LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the

Read more
26 Oct 2018 09:20

Sareum Holdings Raises GBP850,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug

Read more
26 Oct 2018 08:38

Sareum raises £850,000 to fund cancer inhibitor

(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.

Read more
1 Oct 2018 11:30

Sareum Swings To Annual Loss After Prior Year Profit From Associates

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at

Read more
26 Sep 2018 15:20

Sareum Holdings selects cancer therapy development candidate

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.

Read more
26 Sep 2018 14:05

Sareum Selects Candidate To Develop Cancer Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain

Read more
11 Sep 2018 13:28

Sareum Holdings Expects To Swing To GBP1.5 Million Annual Loss

LONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it

Read more
10 Sep 2018 11:52

Sareum Picks SDC-1801 For Development As Autoimmune Disease Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.